Corneal ulceration associated with Nivolumab use

Jack S. Parker\textsuperscript{ab}, Wyatt Feagin\textsuperscript{c}, Christopher Wang\textsuperscript{d}, Marius Heersink\textsuperscript{e}, John S. Parker\textsuperscript{a}

\textsuperscript{a} Parker Cornea, 1720 University Blvd Suite 503, Birmingham, AL, 35233, USA
\textsuperscript{b} Birmingham, AL, USA
\textsuperscript{c} Alabama Oncology Brookwood, 2022 Medical Center Drive, Suite 628, Birmingham, AL, 35209, USA
\textsuperscript{d} Alabama Eye Ophthalmology Associates, 1009 Montgomery Hwy #200, Birmingham, AL, 35216, USA
\textsuperscript{e} University of Alabama at Birmingham School of Medicine, 1670 University Blvd, Birmingham, AL, 35233, USA

ABSTRACT

Keywords: Cornea, Corneal ulcer, Nivolumab, Opdivo, Peripheral ulcerative keratitis

Purpose: To describe a case of corneal ulceration associated with Nivolumab use.

Observations: An 80-year-old woman treated with Nivolumab for metastatic melanoma developed an intractable corneal ulcer in her left eye, refractory to all therapies – including surgery to cover the ulcer with a conjunctival flap – until topical prednisolone acetate was tried, which was curative.

Conclusions and importance: Nivolumab use may be associated with a form of steroid-responsive corneal ulceration.

1. Introduction

Nivolumab is an immunomodulatory agent with a broadening list of indications including first-line medical treatment for metastatic melanoma and second line for non-small cell lung cancer.\textsuperscript{1} The drug is a monoclonal antibody that targets the PD-1 receptor, and it functions by upregulating the number and activity of circulating T-cells.\textsuperscript{2} Stemming from this mechanism, a number of “immune related adverse events” have been described, including polymyalgia rheumatica, insulin-dependent diabetes, and immune-related pneumonitis, colitis, myocarditis, hepatitis, nephritis, encephalitis, and others.\textsuperscript{3} Ocular side effects have also been reported including conjunctivitis, uveitis, and dry eye syndrome.\textsuperscript{4–5} Here, we present a ocular adverse association with Nivolumab use – corneal ulceration – and describe its features, clinical behavior, and potential importance to oncologists as a harbinger of more serious systemic sequelae.

2. Case description

An 80-year-old white female with no past ocular history and a medical history significant for metastatic mucosal melanoma – treated initially with Nivolumab at the standard dosage (every-other-week infusions of 240mg for a duration of 4 months prior to seeing ophthalmological care) – presented to our clinic complaining of redness, pain, and decreased vision in her left eye of one-month's duration. On exam, her left eye manifested a best-corrected visual acuity (BCVA) of 20/40, moderate injection of the bulbar conjunctiva, and a limbus-involving corneal epithelial defect with underlying infiltrate (Fig. 1). The right eye was asymptomatic with a normal exam and a BCVA of 20/20. Bacterial and fungal cultures and HSV PCR were negative. Corneal sensation was normal bilaterally. Nevertheless, for suspected HSV-keratitis, ganciclovir ophthalmic gel (0.15%) was initiated until topical prednisolone acetate was tried, which was curative.

Conclusions and importance: Nivolumab use may be associated with a form of steroid-responsive corneal ulceration.
dry-eye findings in the contralateral eye), its recurrence at the edge of the conjunctival flap, and its prompt resolution following the administration of topical prednisolone acetate (but, interestingly, not loteprednol etabonate). These findings also argue against a diagnosis of Rosacea-related keratitis, which has been reported to produce a sterile corneal ulceration.3

Although our initial suspicion was a herpetic keratitis based on the lesion’s morphology, the patient’s lack of response to extended medical (and surgical) therapy called this diagnosis into question, as did the multiple negative culture and biopsy results. Moreover, Nivolumab may actually be an effective treatment for herpetic keratitis, since it upregulates and activates the body’s T-cell population, making our original diagnosis additionally unlikely and suggesting an etiology of true autoimmune keratitis.3 Whether our patient had a predisposition to developing ocular autoimmune problems is unknown, because the required laboratory investigations to inform upon that issue were not performed. However, it is possible that some individuals may be uniquely susceptible to such complications.

It is also noteworthy that our patient’s systemic side effects of Nivolumab use which forced her to discontinue the medication occurred within four months of the appearance of her corneal ulcer. In patients with rheumatoid arthritis, peripheral ulcerative keratitis is often resistant to topical steroid therapy and is a well-known harbinger of severe morbidity and mortality risk. It is conceivable that peripheral ulceration in patients using Nivolumab likewise presages upcoming systemic events.10

4. Patient Consent

Consent to publish the case report was not obtained. This report does not contain any personal information that could lead to the identification of the patient.

Acknowledgments and disclosures

No funding or grant support.

No author has a financial or proprietary interest in any material or method mentioned.

All authors attest that they meet the current ICMJE criteria for Authorship.

References